TABLE 2.
Treatment characteristics; indications; microbiological isolates; dose, duration, and Cmin, and Cmax of linezolid; concomitant medications; and clinical outcome
| Characteristic | Value (%) (n = 90) |
|---|---|
| Type of treatment (no. [%]) | |
| Empirical | 66 (73.3) |
| Targeted | 24 (26.7) |
| Main indication for linezolid (no. [%]) | |
| Pneumonia | 50 (55.6) |
| Complicated skin and soft tissue infection | 10 (11.1) |
| Undocumented febrile episode | 7 (7.8) |
| Osteoarticular infection | 4 (4.4) |
| Mediastinitis | 4 (4.4) |
| Intra-abdominal infection | 4 (4.4) |
| CNSa infection | 3 (3.3) |
| Bacteremia | 2 (2.2) |
| Other | 6 (6.7) |
| Microbiological isolate (no. [%]) | |
| Coagulase-negative Staphylococcus | 13 (14.4) |
| Staphylococcus aureus | 9 (10) |
| Enterococcus faecalis | 2 (2.2) |
| Enterococcus faecium | 1 (1.1) |
| Enterococcus sp. | 1 (1.1) |
| Corynebacterium sp. | 1 (1.1) |
| Linezolid treatment | |
| Duration of treatment (days) (median [IQR]) | 8.0 (5.0–13.2) |
| Dose (mg/kg) (median [IQR]) | 8.8 (7.5–10.0) |
| Route of administration (no. IV/no. oral) | 61/29 |
| Cmin (mg/liter) (median [IQR]) | 2.9 (0.7–7.7) |
| Cmax (mg/liter) (median [IQR]) | 11.9 (7.8–17.9) |
| Concomitant medication (no. [%]) | |
| Phenobarbital | 0 (0) |
| Dexamethasone | 4 (4.4) |
| Rifampin | 1 (1.1) |
| Proton pump inhibitor | 70 (77.8) |
| Calcium channel antagonist | 11 (12.2) |
| Amiodarone | 5 (5.6) |
| Overall outcome (no. [%]) | |
| Favorable | 66 (73.3) |
| Poor | 24 (26.7) |
a
CNS, central nervous system.